Navigation Links
Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations

- Chairman and CEO Honors the Anniversary by Ringing The Closing Bell(R) at

the NYSE on April 4 -

IRVINE, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today announced its 50th anniversary of partnering with clinicians to develop life-saving innovations. To celebrate its five decades of innovation and success, and eight years as an independent company, Michael A. Mussallem, Edwards' chairman and CEO, will visit the New York Stock Exchange (NYSE) tomorrow afternoon to ring The Closing Bell(R), signaling the end of the trading week. A live webcast of The Closing Bell(R) will be available at beginning at 3:55 p.m. EDT on April 4, 2008.

Edwards' 50-year history dates back to 1958, with the development of the first commercially available artificial heart valve by Miles "Lowell" Edwards and Dr. Albert Starr. The company built on this legacy by innovating a number of other pioneering products including the first -- and only -- biomechanically engineered tissue heart valve; the first heart valve repair ring; the first embolectomy catheter to remove obstructions in blood vessels; the first pulmonary artery catheter, which established the foundation for hemodynamic monitoring; and more recently, the first "beating heart" transcatheter aortic valve replacement.

"We take great pride in our 50-year heritage of working as trusted partners with clinicians to develop innovative technologies that transform patient care," said Mussallem. "We believe Lowell Edwards would be very proud of the company that bears his name today and the more than 5,600 employees worldwide who carry on his mission to provide treatments and hope for patients with advanced cardiovascular disease."

"It brings me tremendous joy that the replacement heart valves Lowell Edwards and I co-developed 50 years ago began a company that today continues to pioneer live-saving cardiovascular devices and procedures," said Dr. Albert Starr, medical director of the Providence Heart and Vascular Institute and co-recipient of a 2007 Lasker Award for the development of artificial heart valves. "I'm proud of my enduring association with Edwards Lifesciences and look forward to the company's continued success helping millions of patients worldwide."

In 1958, Lowell Edwards was a 60-year-old recently retired engineer with 63 patents in an array of industries, an entrepreneurial spirit and dreams of helping patients with heart disease. With a background in hydraulics and fuel pump operations, he believed the human heart could be mechanized. He presented the concept to Dr. Starr, a young surgeon at the University of Oregon Medical School, who encouraged Lowell Edwards to focus first on developing an artificial heart valve, for which there was an immediate need. After only two years, the first Starr-Edwards mitral valve was designed, developed, tested and successfully placed in a patient.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. The Closing Bell is a registered trademark of the New York Stock Exchange, Inc.

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
2. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
3. Edwards Lifesciences Announces Organizational Changes
4. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
6. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
7. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
8. Edwards Lifesciences Forecasts Strong Growth in 2008
9. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
10. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
11. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):